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Hypertension and chronic kidney disease (CKD) are complex 
traits representing major global health problems1,2. Multiple 
genome-wide association studies have identified common 
variants in the promoter of the UMOD gene3–9, which encodes 
uromodulin, the major protein secreted in normal urine, that 
cause independent susceptibility to CKD and hypertension. 
Despite compelling genetic evidence for the association 
between UMOD risk variants and disease susceptibility in 
the general population, the underlying biological mechanism 
is not understood. Here, we demonstrate that UMOD risk 
variants increased UMOD expression in vitro and in vivo. 
Uromodulin overexpression in transgenic mice led to salt-
sensitive hypertension and to the presence of age-dependent 
renal lesions similar to those observed in elderly individuals 
homozygous for UMOD promoter risk variants. The link 
between uromodulin and hypertension is due to activation 
of the renal sodium cotransporter NKCC2. We demonstrated 
the relevance of this mechanism in humans by showing that 
pharmacological inhibition of NKCC2 was more effective 
in lowering blood pressure in hypertensive patients who are 
homozygous for UMOD promoter risk variants than in other 
hypertensive patients. Our findings link genetic susceptibility 
to hypertension and CKD to the level of uromodulin expression 
and uromodulin’s effect on salt reabsorption in the kidney. 
These findings point to uromodulin as a therapeutic target for 
lowering blood pressure and preserving renal function.
Current understanding of the complex genetic architecture of hyper-
tension and CKD stems from the identification of mutations causing 
rare inherited disorders10,11 and of several susceptibility loci through 
population-based association studies12–14. However, deciphering the 
biological mechanisms underlying these genetic associations has 
proven to be a major challenge.
Recent genome-wide association studies (GWAS) in more than 
200,000 individuals of European ancestry have identified susceptibil-
ity variants for renal function, CKD and hypertension in the UMOD 
gene encoding uromodulin3–9. Uromodulin (or Tamm-Horsfall pro-
tein) is the most abundant urinary protein and is specifically pro-
duced and secreted by the epithelial cells lining the thick ascending 
limb (TAL) of the loop of Henle in the kidney15. Studies in Umod 
knockout mice revealed that uromodulin may protect against urinary 
tract infection16 and kidney stones17 and modulate electrolyte tubu-
lar transport18. Recent evidence suggests that uromodulin regulates 
the activity of the sodium-potassium-chloride transporter (NKCC2) 
and the renal outer medullary potassium channel (ROMK), the two 
main ion transporters involved in NaCl reabsorption by the TAL 
segment19,20. Mutations in UMOD have been associated with rare 
dominantly inherited disorders causing kidney damage and CKD21. 
The observation that susceptibility variants in the UMOD gene have a 
high frequency (about 0.8) in the general population and confer about 
20% increased risk for CKD and 15% for hypertension emphasizes the 
pressing need to understand the nature of their associated risk and 
how they affect uromodulin function22.
Given the localization of the most significant (lead) single nucleo-
tide polymorphisms (SNPs) identified by GWAS in a linkage disequi-
librium block that includes the UMOD gene promoter (Fig. 1a), we 
hypothesized that these variants could be associated with an effect 
on gene expression. We tested this hypothesis in vivo by measuring 
UMOD transcript levels in nephrectomy samples from individuals 
homozygous for either the risk or protective alleles at lead variants 
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rs12917707 and rs4293393, which are both localized in the UMOD 
promoter. Carriers of the UMOD promoter risk variants showed 
twofold higher UMOD expression in kidney samples compared to carri-
ers of the protective haplotype (Fig. 1b). We confirmed the association 
of UMOD promoter risk variants with higher uromodulin expression 
by showing a similar dose-dependent increase in urinary uromodu-
lin levels in a large population-based cohort (SKIPOGH) (Fig. 1c). 
In silico analysis revealed that among the lead SNPs from GWAS, 
rs4293393 maps to a highly conserved region of the UMOD promoter 
(Supplementary Fig. 1) and is predicted to lie within a glucocorticoid 
response element, such that the protective allele would disrupt this 
element (Fig. 1d). We hence tested whether the risk and protective 
alleles at this SNP affected the transcriptional activity of the human 
UMOD gene promoter. We performed a standard in vitro luciferase 
reporter assay employing a 3.7-kilobase (kb) UMOD promoter frag-
ment in three different types of renal cells, including highly differen-
tiated mouse TAL primary cells that retain high Umod expression. 
Notably, the risk allele increased the expression of the luciferase 
reporter relative to the protective allele by about twofold in each of 
the types of cells tested (Fig. 1e), in accord with the in vivo find-
ings. We also confirmed the predicted effect of the rs4293393 risk 
allele on the promoter response to glucocorticoids (Supplementary 
Fig. 2). The finding that glucocorticoids induced transcription from 
both constructs is in line with the presence of additional predicted 
glucocorticoid response elements in the UMOD promoter (prediction 
data not shown) and suggest that uromodulin expression is subject to 
complex hormonal regulation. Overall, these results demonstrate that 
the UMOD promoter risk variant rs4293393, probably acting together 
with other variants within the same linkage disequilibrium block, is 
associated with higher uromodulin expression.
To model this effect in vivo, we took advantage of a transgenic mouse 
line expressing hemagglutinin (HA)-tagged wild-type uromodulin 
(Tg(Umod)416Lura, here referred to as TgUmodwt mice). We also 
generated a line homozygous for the transgene (TgUmodwt/wt mice). 
Transgenic animals from both lines were viable, apparently healthy and 
indistinguishable from control nontransgenic mice (here referred to as 
control mice). The presence of the transgene caused a dose-dependent 
increase in uromodulin expression and secretion (Supplementary 
Fig. 3a–c). Notably, uromodulin was expressed at approximately 80% 
higher amounts in TgUmodwt/wt mice relative to control mice, compa-
rable to the effect on uromodulin expression in subjects homozygous 
for UMOD risk variants. Similarly to endogenous uromodulin, the 
transgenic protein was expressed exclusively in TAL segments of the 
nephron (Supplementary Fig. 3d–f; see also ref. 23).
As uromodulin is expressed in the TAL, a tubular segment that has 
been implicated in rare inherited disorders characterized by defective 
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Figure 1 Effects of UMOD SNP variants on uromodulin expression. (a) Schematic representation of human UMOD gene structure. The positions of lead 
SNPs in the UMOD promoter associated with hypertension and CKD are shown. All variants are within the same linkage disequilibrium block, as shown 
by the linkage disequilibrium plot (r2 values, data from HapMap CEU, release #28). Genotyped SNPs are shown in red. (b) UMOD expression levels 
(quantitative RT-PCR (qRT-PCR)) in nephrectomy samples of individuals homozygous for either protective (n = 17) or risk (n = 27) alleles for UMOD 
promoter variants rs12917707 and rs4293393. All samples were genotyped for both variants. We normalized UMOD expression to NKCC2 to account for 
differing TAL content in the samples. Each dot represents an individual, and the distribution and mean values of expression levels are shown. ***P < 0.001 
(Mann-Whitney test). (c) Urinary uromodulin concentrations in individuals of the SKIPOGH cohort by genotype at rs4293393 (n = 18 CC, n = 214 CT and  
n = 532 TT). Data are expressed as means ± s.e.m. The P value reflects significant association of rs4293393 genotype with square-root–transformed daytime 
urinary uromodulin-to-creatinine ratio in a mixed linear model. C, protective allele; T, risk allele. (d) Partial alignment of human (Hs), gorilla (Gg), gibbon (Nl), 
macaque (Mm), cow (Bt) and dog (Cf) UMOD promoter sequences. The intensity of the blue color shading corresponds to nucleotide conservation (the darker 
the color, the higher the degree of nucleotide conservation). The rs4293393 SNP is predicted to lie within a glucocorticoid response element; the protective 
(C) allele would disrupt this predicted binding site. T, risk allele. (e) Quantitative analysis of the relative effects of the protective (C) and risk (T) alleles of 
SNP rs4293393 on the transcriptional activity of UMOD promoter as assessed by a luciferase reporter assay in three types of kidney cells: mTAL, (highly 
differentiated mouse primary TAL cells retaining uromodulin expression), immortalized MKTAL (mouse kidney TAL) and HEK293 (human embryonic kidney) 
cells. The data are from four independent experiments. The schematic shows the luciferase reporter constructs used, in which a 3.7-kb UMOD promoter 
fragment containing either the C or T allele was cloned upstream of the firefly luciferase (LUC) gene in the pGL3-Basic reporter vector (Basic corresponds to 
the promoterless vector). Data are expressed as means ± s.e.m. **P < 0.01; ***P < 0.001 (ANOVA followed by Bonferroni’s test).
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NaCl reabsorption and low blood pressure10, we first tested whether 
uromodulin overexpression could affect blood pressure by having an 
effect on NaCl reabsorption. Blood pressure was indeed markedly 
higher in transgenic mice relative to control mice in a Umod dosage– 
dependent fashion (P < 0.0001, analysis of variance (ANOVA) 
post hoc test for linear trend) (Fig. 2a). Blood pressure in TgUmodwt/wt 
mice was significantly higher relative to control mice as early as 
2 months of age, and the difference in blood pressure increased with 
age. This age-dependent effect was partly due to low blood pressure in 
aging control mice, as previously described24,25 (Fig. 2a). High blood 
pressure in TgUmodwt/wt mice was associated with a significant increase 
of the total heart mass and left ventricular hypertrophy, consistent 
with a chronic hypertensive state (Fig. 2b). Hypertension in trans-
genic mice was salt sensitive, as blood pressure could be normalized to 
control levels by a low-NaCl diet but returned to elevated levels upon 
return to a standard NaCl diet (Fig. 2c). The changes in dietary salt 
exposure also caused the expected modifications in aldosterone levels 
and NaCl handling, which were similar in control and transgenic 
animals (Supplementary Fig. 4).
Transgenic mice had a similar body weight and baseline urine 
and plasma parameters relative to control mice up to 16 months 
of age (Supplementary Table 1 and data not shown). Renal func-
tion, as measured by FITC-sinistrin clearance26, was also normal 
(Supplementary Table 1). However, histological analysis of kid-
neys from aging TgUmodwt/wt mice revealed signs of renal damage, 
mainly localized to and affecting distal segments, with segmen-
tal dilation and increased tubular cast area relative to control mice 
(Fig. 2d and Online Methods). We detected similar focal lesions in 
human nephrectomy samples from individuals older than 65 years 
of age, and the area of these lesions was increased in individuals 
homozygous for UMOD risk variants relative to those homozygous 
for protective variants (Fig. 2e and Online Methods). Further inves-
tigation in TgUmodwt/wt mice revealed that tubular casts often but not 
always stained positive for uromodulin and localized to TALs and 
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16-month-old control and TgUmodwt/wt mice normalized to the loading control, β-actin. Data are expressed as means ± s.d. *P < 0.05; **P < 0.01;  
***P < 0.001 determined by unpaired t-test (a (left), b,c and h), ANOVA followed by Bonferroni’s test (a (right) and g) or Mann-Whitney test (d and e).
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more distal segments (Fig. 2f). Evidence of renal damage in trans-
genic mice also included increased renal expression of established 
markers of tubule damage (Lcn2, encoding lipocalin 2 (Lcn2), 
and Havcr1, encoding kidney injury molecule-1 (Kim-1)) and the 
chemokines Ccl2 and Ccl5 (Fig. 2g,h), and transgenic mice also had 
substantial microalbuminuria (data not shown). There was also a sig-
nificant dilation of glomerular capillary loops in these mice (Fig. 2d 
and Supplementary Fig. 5a). There were no signs of interstitial vas-
cular remodeling in the kidney that could be ascribed to chronic 
hypertension (Supplementary Fig. 5b), in line with the fairly rapid 
BP response induced by changes in dietary salt (see above).
In the context of the normal renal function of Umod transgenic 
mice, which showed normal or slightly decreased renin expression 
(Supplementary Fig. 6), we hypothesized that the salt-sensitive hyper-
tension of the transgenic mice could be caused by abnormal activation 
of Nkcc2, the main sodium transporter in the TAL. Consistent with this 
hypothesis, we found a significantly higher level of phosphorylation on 
Nkcc2 at activating sites (Thr96 and Thr101)27,28 in TgUmodwt/wt mice rela-
tive to control mice (Fig. 3a). The increase in phosphorylated Nkcc2 levels 
was linearly correlated with Umod gene dosage (P < 0.01, ANOVA post hoc 
test for linear trend). The specificity of this effect for phosphorylation on 
Nkcc2, rather than on Nkcc1, which can also be recognized by the anti-
bodies used in this experiment, is supported by the almost exclusive locali-
zation of the phosphorylated protein signal on the apical membrane of 
TAL cells, which lacks Nkcc1, and by the 40-fold higher global expression 
of Nkcc2 as compared to Nkcc1 in the kidney (Supplementary Fig. 7a,b). 
In line with a post-translational mechanism for the regulation of Nkcc2, 
Nkcc2 transcript levels were not different between transgenic and control 
mice (Fig. 3b). Romk expression and membrane localization were similar 
in transgenic and control mice (Supplementary Fig. 8a–c).
To test the functional importance of Nkcc2 to the hypertensive pheno-
type of Umod transgenic mice, we assessed the response of these mice to 
furosemide, a loop diuretic that specifically targets NKCC2. Treatment 
of TgUmodwt/wt mice with a single dose of furosemide induced both a sig-
nificantly enhanced natriuretic effect and a significant reduction of blood 
pressure (Fig. 3c). The enhanced response of transgenic mice compared 
to control mice to furosemide treatment is probably due to increased 
Nkcc2 activity and increased sodium reabsorption in the TAL rather than 
to adaptive downregulation of NaCl reabsorption in more distal neph-
ron segments, as control and transgenic mice had comparable levels of 
sodium-chloride symporter (Ncc) (distal convoluted tubules) and epithe-
lial sodium channel (ENaC) (collecting ducts) (Supplementary Fig. 8d,e), 
as well as similar levels of aldosterone (Supplementary Fig. 4b).
We next investigated the direct effect of uromodulin on Nkcc2 activa-
tion in kidney cells stably expressing Nkcc2 and transiently transfected 
with either human wild-type uromodulin or with a soluble uromodulin 
isoform truncated at the glycosylphosphatidylinositol (GPI)-anchoring 
site (S614X)29. Expression of wild-type uromodulin led to a significant 
increase in Nkcc2 phosphorylation that correlated with an increase in 
its activity (Fig. 3d,e). The effect on Nkcc2 phosphorylation and activity 
was completely lost in cells transfected with soluble uromodulin. These 
findings confirm in a mammalian system the previously described effect 
of uromodulin on NKCC2 phosphorylation and activity19 and strongly 
suggest that this effect is exerted by membrane-anchored uromodulin.
NKCC2 phosphorylation is, at least in part, mediated by STE20/
SPS1-related proline-alanine–rich kinase (SPAK) and by oxidative 
stress response 1 kinase (OSR1)30,31. The level of Spak phosphorylated 
at Thr243 (i.e., active Spak) relative to total Spak was significantly 
increased in TgUmodwt/wt mice compared to control mice, and there 
was also a trend towards an increase in the level of phosphorylated 
Osr1 (at Thr185) relative to total Osr1 in TgUmodwt/wt mice (Fig. 3f 
and Supplementary Fig. 7c). These data demonstrate upregulation 
of this regulatory network by uromodulin overexpression. Consistent 
with this effect, the transcript level of kidney-specific Spak, an isoform 
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Figure 3 Increased activation of Nkcc2 co-transporter and Spak kinase in TgUmodwt/wt mice. (a) Representative immunoblot images and quantitative 
data (n = 10–13 mice per group) showing levels of phosphorylated (Thr96 and Thr101) Nkcc2 (p-Nkcc2) and total Nkcc2 in kidney lysates from  
16-month-old mice. Data are expressed as means ± s.d. of four independent experiments. #, unspecific signal. Calnexin was used as a loading control. 
(b) Nkcc2 mRNA (qRT-PCR) in total kidney extracts from 16-month-old mice (n = 5 per group). Data are expressed as means ± s.e.m. (c) Change in 
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Data are from eight independent experiments and are expressed as means ± s.e.m. (f) Representative immunoblot images and quantitative data  
(n = 4 mice per group) showing levels of phosphorylated and total Spak and Osr1 in kidney lysates from 16 month-old control and TgUmodwt/wt mice. 
Bars indicate means ± s.d. *P < 0.05; **P < 0.01 determined by ANOVA followed by Bonferroni’s test (a,b,d and e) or unpaired t test (c and f).
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which is expressed mainly in the TAL and which acts as a negative 
regulator of Nkcc2 phosphorylation32, but not that of full-length Spak, 
was reduced in transgenic mice (Supplementary Fig. 7d,e).
Finally, to investigate whether UMOD variants could have a role in 
modulating blood pressure in humans, we took advantage of a well-
characterized cohort of naive (never-treated) hypertensive subjects 
(MI_HPT cohort) stratified a posteriori for their rs4293393 SNP sta-
tus (Supplementary Table 2). Baseline mean diastolic blood pressure 
was significantly higher in hypertensive individuals homozygous 
for the risk allele relative to individuals that were heterozygous or 
were homozygous for the protective allele (Fig. 4a). For a subset 
of these subjects, data from furosemide tests were also available. 
Patients homozygous for the risk allele showed an increased diu-
retic response,with a significantly higher increase of natriuresis over 
baseline values (Fig. 4b) and a more marked drop in blood pressure, 
with a significant difference in the decrease of DBP and a similar 
trend for SBP (P = 0.06) (Fig. 4c and Supplementary Table 2). 
Despite the limitations of this study, which involved retrospec-
tive analysis of a relatively small-sized cohort, these results suggest 
that the mechanism causing hypertension in transgenic mice (i.e., 
increased NKCC2 activity linked to overexpression of uromodulin) 
may contribute to hypertension in humans.
This work identifies a causal role for a major risk locus for CKD and 
hypertension, which had been identified in multiple GWAS. Studies 
of rare monogenic disorders33 have contributed considerably to our 
current knowledge of the functional relationship between NaCl handling 
in the kidney and blood pressure regulation. Loss-of-function mutations 
impairing sodium reabsorption have been associated with salt wasting 
and reduced blood pressure in monogenic diseases affecting the TAL 
(Bartter’s syndrome) or more distal segments (Gitelman’s syndrome and 
pseudohypoaldosteronism type 1). Thus far, increased sodium reabsorp-
tion leading to hypertension has been linked exclusively to mutations 
affecting these more distal segments (Liddle’s syndrome and pseudo-
hypoaldosteronism type 2)10,14. The new gain-of-function mechanism 
described here completes the paradigm that links renal transport of 
NaCl with blood pressure regulation. This mechanism could be widely 
relevant to human hypertension, given the high frequency of UMOD risk 
variants in the general population (Supplementary Table 3). Further 
prospective studies will be necessary to confirm our findings in patients 
with hypertension and to elucidate the contribution of increased sodium 
transport in the TAL to hypertension.
Through evidence obtained in mouse and cellular models, this study 
establishes the importance of uromodulin in modulating NaCl handling in 
the TAL. Notably, both the expression and urinary excretion of uromodu-
lin are increased by high sodium intake in rats34 and humans35. Here, we 
demonstrate that UMOD promoter activity is modulated by glucocorti-
coids, which are known to have a central role in ion homeostasis and blood 
pressure regulation and have been shown to act on TAL cells36.
Both in aging TgUmodwt/wt mice and in elderly individuals 
homozygous for UMOD promoter risk variants, upregulation of uro-
modulin expression was associated with the presence of focal renal 
lesions, tubular dilation and casts, despite normal kidney function. The 
focal kidney damage observed in TgUmodwt/wt mice seems unlikely to 
be secondary to chronic hypertension, as no such lesions were detected 
in other rodent models of hypertension37. Rather, these lesions, as well 
as the upregulation of Lcn2 and Kim-1 expression, are reminiscent 
of changes observed in aging kidneys38,39. These results suggest that 
uromodulin overexpression is unlikely to lead to renal failure per se, 
but could predispose to CKD. In this scenario, CKD, whose incidence 
increases with age, would be triggered by additional conditions harm-
ing the kidney. This hypothesis is supported by recent evidence that 
the association of UMOD promoter risk variants with CKD is stronger 
in the older age groups with additional comorbid conditions7,9.
Our study shows that common variants in a gene associated with 
a rare monogenic disorder may play a causal role in complex traits 
in the general population. UMOD risk variants are present in a high 
frequency in all ethnic groups studied (Supplementary Table 3), sug-
gesting the action of selective pressure. Selective pressure for a dis-
ease-associated variant is atypical but not unprecedented; for example, 
APOL1 variants are strongly associated with kidney disease in African 
Americans but increase resistance to Trypanosoma brucei rhodesiense 
infection40. We speculate that selective pressure might have favored 
UMOD variants leading to high expression and urinary levels of uro-
modulin due to its protective effect in urinary tract infections and its 
stimulation of renal salt reabsorption. However, with increased life 
expectancy, better hygienic conditions and higher salt intake, these 
same variants could now be exerting a deleterious effect. Accordingly, 
therapies targeting uromodulin expression or function may be rel-
evant for controlling blood pressure and preserving renal function.
MeTHODs
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 4 Increased blood pressure and response to furosemide in 
hypertensive patients homozygous for UMOD risk variants. (a) Average 
values for systolic (SBP) and diastolic (DBP) blood pressure in individuals 
homozygous for the rs4293393 risk genotype (TT) and for individuals 
either homozygous for the protective genotype or heterozygous  
(CC + CT), as assessed by 24-h ambulatory blood pressure monitoring.  
(b,c) Response to furosemide treatment in hypertensive patients with the 
indicated rs4293393 genotypes. Changes in sodium excretion (b) and 
SBP and DBP (c) 4 h after treatment are shown. Data are expressed as 
means ± s.e.m. (a and c) or means ± s.d. (b). *P < 0.05 (ANOVA).
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ONLINe MeTHODs
MI_HPT cohort. The MI_HPT cohort study was approved by the Comitato 
Etico Ospedale San Raffaele, the ethical committee of the San Raffaele Hospital. 
All participants provided informed written consent.
In this study, we enrolled a cohort of 471 (391 males and 80 females) never-
treated hypertensive patients referred to the Outpatient Clinic at San Raffaele 
Hospital41. Patients were between 20 and 65 years old and each had a body 
mass index <30 kg/m2 and systolic and diastolic blood pressure (SBP/DBP) 
>140/90 mm Hg and <160/110 mm Hg. We excluded from the study patients 
with chronic or acute pathologies, clinical history for ischemic cardiomy-
opathy, cardiac decompensation, cerebral vasculopathy, creatinine clearance 
<80 ml min−1, liver failure, diabetes, severe essential hypertension or second-
ary arterial hypertension. We also excluded subjects under antihypertensive or 
estrogen or progestin therapy or with a history of addiction and/or alcohol abuse. 
We gave patients dietary instructions including a list of suggested and forbidden 
foods and verified compliancy by assessing 24-h urinary sodium excretion.
SKIPOGH cohort. The Swiss Kidney Project on Genes in Hypertension 
(SKIPOGH) study was approved by Commission d’éthique de la recherche cli-
nique, the ethical committee of Lausanne University Hospital, the Commission 
centrale d’éthique, the ethical committee of Geneva University Hospitals and the 
Kantonale Ethikkommission Bern, the ethical committee of University Hospital 
of Bern (Inselspital). All participants provided informed written consent.
The SKIPOGH study is a family-based cross-sectional study exploring the role of 
genes in blood pressure and kidney function regulation. We recruited participants 
from December 2009 until April 2013 in three centers (Bern, Geneva and Lausanne 
in Switzerland), as previously described42. Participants collected urine during the 
daytime, which had a median duration of 16 h (interquartile range, 2). The analysis 
of uromodulin urinary levels was performed for all available samples.
Human kidney samples. The study on adult human kidney samples was approved 
by the Comitato Etico Ospedale San Raffaele, the ethical committee of the San 
Raffaele Hospital. All participants provided informed written consent. Human 
renal samples were from individuals who underwent nephrectomy at the San 
Raffaele Hospital because of renal carcinoma. Samples of normal tissue were 
dissected, fixed in 4% buffered formaldehyde, embedded in paraffin and sub-
sequently cut into 3-µm sections for histology. Tissue samples were stored in 
RNAlater (Qiagen) at −80 °C for molecular analysis. Only kidneys from patients 
with normal renal function (i.e., eGFR > 90 ml min−1, calculated by using the 
four-variable Modification of Diet in Renal Disease formula43) and from patients 
not under antitumor treatment at the time of explant were eligible for this study. 
We matched individuals homozygous for the rs12917707 and rs4293393 protec-
tive alleles (n = 17; 41.2% females; age at the time of nephrectomy 67.7 ± 12.7 
years) for age and sex with at least one individual homozygous for the risk alleles 
(n = 27; 33.3% females; age at the time of nephrectomy 67.9 ± 9.6 years).
Genotyping. We carried out genotyping in individuals in the MI_HPT cohort 
and in individuals who underwent nephrectomy on genomic DNA extracted 
from blood samples or renal tissue, respectively. We used the QIAamp DNA 
Mini Kit (Qiagen) and carried out 5′ nuclease allelic discrimination assays 
with allele-specific MGB probes (TaqMan, Applied Biosystems) for marker 
SNPs rs4293393 (Assay ID C__27865986_10) and rs12917707 (Assay ID C__
31122302_10) according to manufacturer’s instructions (call rate of 97.2%).
Genotyping of SNP rs4293393 in individuals in the SKIPOGH cohort was 
performed on genomic DNA extracted from white blood cells at LGC Genomics 
(formerly KBioscience) using the Competitive Allele Specific PCR technique 
(KASPar v4.0) (call rate of 96.4%). Additional quality-control criteria included 
inter- and intraplate duplicate testing and clear separation of signal clusters.
A reproducibility test on randomly selected duplicates (10% in the MI_HPT 
and 4.5% in the SKIPOGH cohorts) showed 100% concordance. The frequency 
of the rs4293393 minor allele C was 0.180 in the MI_HPT cohort and 0.163 in 
the SKIPOGH cohort. The P values for Hardy-Weinberg equilibrium were 0.048 
(MI_HPT) and 0.34 (SKIPOGH). The deviation in the MI_HPT cohort was 
driven by underrepresentation of individuals homozygous for the protective 
allele C (observed 9 versus expected 15.3). This finding is in line with GWAS 
showing association of the risk allele T with hypertension3.
Patient ambulatory blood pressure monitoring and furosemide test. Patients 
in the MI_HPT cohort (n = 471) underwent 24-h ambulatory blood pressure 
monitoring (Spacelab 90207; Spacelab Medical) on a day chosen for typical 
weekly activity. Recordings were performed every 10 min during waking hours 
(daytime) and every 30 min during nighttime.
Owing to the low frequency of the rs4293393 protective allele, we grouped 
patients carrying one (CT, n = 152) or two (CC, n = 9) copies of the protec-
tive variant and compared them with those homozygous for the risk variant 
(TT, n = 310). The two groups did not significantly differ by age, sex, BMI or 
renal function (see Supplementary Table 2).
A subgroup of 165 patients underwent a furosemide test, as follows. After 2 h 
equilibration, we orally administered 25 mg of furosemide (Sanofi-Aventis). We 
collected urine immediately before and 4 h after furosemide administration. We 
measured BP every 60 min during the equilibration period and every 30 min 
after furosemide treatment. Reported values are the average of three measure-
ments done every minute at each of the timepoints. As for ambulatory blood 
pressure monitoring, we grouped patients carrying one (CT, n = 44) or two (CC, 
n = 3) copies of the protective variant and compared them with homozygous 
for the risk variant (TT, n = 118). The two groups did not significantly differ in 
age, sex, BMI or renal function.
We measured urinary Na+ by flame photometry, creatinine by picric acid 
test and plasma renin activity by commercial radioimmunoassay (Sorin 
Laboratories).
Human urinary uromodulin measurements. We measured urinary uro-
modulin concentration by ELISA using on a sheep anti-human uromodulin 
antibody (Meridian Life Science, K90071C, 5 µg ml−1) as the capture anti-
body, a mouse monoclonal anti-human THP antibody (Cedarlane, CL1032A, 
1 µg ml−1) as the primary antibody and a goat anti-mouse IgG (H+L) horse-
radish peroxidase–conjugated antibody (BioRad, 1721011, 1:2,000) as the sec-
ondary antibody44. We used human uromodulin (Millipore, stock solution 
100 µg ml−1) to establish the standard curve45. The uromodulin ELISA assay 
had a sensitivity of 2.8 ng ml−1, a linearity of 1.0, an interassay variability of 
3.3% and an intra-assay variability of 5.5% . We measured urinary creatinine 
levels using Beckman Coulter Synchron System Creatinine Assay (Unicell DxC 
Synchron Clinical System)46 following the manufacturer’s instructions. We nor-
malized uromodulin concentration to creatinine concentration (uromodulin- 
to-creatinine ratio) to compensate for variations in urine concentration.
Transgenic mice. We generated TgUmodwt mice as described previously23. 
Briefly, we injected the FVB/N mouse strain with the transgenic uromodulin 
construct composed of a 2.9-kb fragment of the Umod gene promoter, the first 
noncoding exon, the first intron, the coding sequence from exon 2 to 11 and 
the entire 3′ untranslated region. An HA tag was inserted at the uromodulin 
N terminus. We generated TgUmodwt/wt mice by breeding TgUmodwt mice and 
verified transgene homozygosity by Southern blot analysis. The two transgenic 
lines are in pure FVB/N background. Control mice were nontransgenic ani-
mals in the same isogenic background. We carried out all animal procedures on 
female mice at San Raffaele Scientific Institute, Milan, Italy, and at Université 
Catholique de Louvain, Brussels, Belgium, according to protocols approved 
by the San Raffaele Institutional Animal Care and Use Committee and by the 
Belgian National Research Council Guide for the Care and Use of Laboratory 
Animals/Animal Ethics Committee, respectively.
Plasma and urine collection and analysis.  We obtained urine and plasma 
from age- and gender-matched transgenic and control mice. Mice were housed 
in a light- and temperature-controlled room with ad libitum access to tap water 
and standard chow (Diet AO3, SAFE; 25/18 GR Mucedola Srl) or low-sodium 
chow (E15430-24, SSNIFF). We collected urine using individual metabolic 
cages (14 h overnight for baseline measurement and 2 h after furosemide 
administration, 10 mg per kg body weight) after appropriate training of the 
mice. We obtained blood by venous puncture or at the time of killing by 
decapitation. Sampling procedures were identical in all groups. We measured 
urinary electrolytes, creatinine and albumin, plasma electrolytes, creatinine 
(enzymatic determination), urea and uric acid on a Synchron CX5 analyzer 
(Beckman Coulter) and measured aldosterone using a validated Aldosterone 
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EIA kit (Cayman Chemical) according to the manufacturer’s instruc-
tions and normalizing to urinary creatinine (Beckman Coulter Synchron 
System Creatinine Assay). We measured osmolality on a Fiske osmometer 
(Advanced Instruments).
Mouse blood pressure measurements. We measured systolic BP by the 
tail-cuff method (Physiograph Narco or BP-2000, Visitech Systems) on two 
different days in conscious animals after appropriate training of the mice. 
We averaged four to six successive measurements.
Tissue collection and preparation. To collect organs (kidney, heart, spleen, 
brain, adrenal glands, aorta and testis), the mice were killed by decapitation 
or cervical dislocation after anesthesia with Sevoflurane (Abbott). We imme-
diately homogenized organs for protein or RNA extraction. We fixed renal 
and cardiac tissue in 4% paraformaldehyde before embedding in paraffin for 
histological, immunohistochemical and immunofluorescence analysis.
Cell cultures. We maintained human embryonic kidney (HEK) 293 cells 
in DMEM supplemented with 10% FBS (Invitrogen) and 1% penicillin/
streptomycin. MKTAL cells are an immortalized TAL line isolated and char-
acterized by Bourgeois et al.47. We cultured MKTAL cells in DMEM:F12 (1:1) 
with the SingleQuots Kit (Lonza) containing hydrocortisone, hEGF, FBS, epine-
phrine, insulin, triiodothyronine, transferrin and gentamicin/amphotericin. 
We obtained TAL primary cultures (mTAL) from microdissected tubules of 
the outer medulla of 5-week-old collagenase-treated C57BL/6 mouse kidneys 
according to the method described by Terryn et al.48. We selected TAL tubules 
on the basis of their morphology49 and cultured them on permeable filter 
supports for 14 d, allowing the formation of well-polarized confluent monol-
ayers. These monolayers are characterized by morphological, functional and 
structural properties similar to those of the TAL segment in vivo, including a 
high level of endogenous uromodulin expression49. We kept cells at 37 °C in 
a humidified atmosphere containing 5% CO2.
Constructs. We cloned a 3.7-kb fragment of the human UMOD gene promoter 
containing the risk allele at the SNP rs4293393 (nucleotide −551 T) into the 
pGL3-Basic Luciferase Reporter vector (Promega) in two steps. We obtained 
the promoter region from nucleotide +1 to −1092 by PCR using primers with 
MluI (forward, 5′-TTACGCGTCACGTTGTGCACTTGTACCC-3′) and 
XhoI (reverse, 5′-TCTCGAGTGGTCATGATGTGCCTCATAC-3′) tails, and 
the promoter region from nucleotide −1093 to −3684 by PCR using primers 
with SacI (forward, 5′-TTGAGCTCATTCAGGACACGGTGTAAGG-3′) and 
MluI (reverse, 5′-TTACGCGTCAGGTTTGTTACATATGTATAC-3′) tails. We 
generated the promoter construct containing the rs4293393 protective allele 
(nucleotide −551 C) by site-directed mutagenesis using the QuickChange 
Lightning Site-Directed Mutagenesis Kit (Stratagene, Agilent) following the 
manufacturer’s protocol. We confirmed all plasmids by sequencing.
We cloned HA-tagged human wild-type uromodulin (WT UMOD) and 
truncated uromodulin soluble isoform (Sol. UMOD), which lacks the GPI-
anchoring site (S614X), into the expression vector pcDNA3.1 (+) (Invitrogen), as 
previously described29.
UMOD promoter activity in vitro. We tested the effect of rs4293393 
protective and risk alleles on the transcriptional activity of the UMOD pro-
moter in mTAL, MKTAL and HEK293 cells. Whereas mTAL cells retain high 
uromodulin expression consistent with their fully differentiated state, weak 
or no uromodulin expression was detected in MKTAL and HEK293 cells, 
respectively (qRT-PCR, data not shown).
We transiently transfected mTAL, MKTAL and HEK293 cells with 2 µg of a 
firefly luciferase reporter plasmid (pGL3-Basic, Promega), either promoterless 
or carrying UMOD promoter fragments (see constructs paragraph) and 10 ng 
of a Renilla luciferase vector (pRL-SV40, Promega) using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions.
We evaluated luciferase activity 48 h after transfection with the Dual-
Luciferase Reporter Assay System (Promega) using a GloMax 96 luminometer 
(Promega) with 10 s of integration time (the duration of measurement per well). 
Firefly luciferase activity was corrected for transfection efficiency using meas-
urement of Renilla luciferase activity. We used the promoterless pGL3-Basic 
vector as a negative control. To assess the response of the UMOD promoter to 
glucocorticoids, 24 h after transfection cells were treated with 1 µM dexametha-
sone (Sigma) and/or 10 µM RU-486 (Sigma) for 48 h. For each combination of 
UMOD allele and cell type, we carried out at least four independent transfections 
and assayed extracts in duplicate.
Nkcc2 cotransporter activity in vitro. We cloned a construct containing a 
cDNA for mouse Nkcc2 with a Myc tag fused to its N-terminus into the pTar-
get expression vector (Promega). To generate HEK293 cells stably expressing 
Nkcc2, we transfected the cells, selected for resistance to geneticin (G418, 
500 µg ml−1) and isolated single clones. We performed all experiments on 
the same clone. We carried out transient transfection of plasmids expressing 
full-length or truncated uromodulin or empty vector using Lipofectamine 
and Plus Reagent (Invitrogen) according to the manufacturer’s instructions. 
Equal expression of the two transfected uromodulin isoforms was verified by 
qRT-PCR (data not shown).
We measured Nkcc2 cotransport activity as bumetanide-sensitive NH4 influx 
as previously described50. Briefly, we used the intracellularly trapped pH-sensi-
tive dye BCECF to measured cytoplasmic pH (pHi) in cells grown to confluence 
on coverslips. We measured baseline pHi in cells bathed at 37 °C in a CO2-free 
Hepes-Tris buffered medium. We then added NH4Cl (20 mM) to the medium 
to induce cellular alkalinization and measured the initial rate of intracellular pH 
recovery (dpHi dt−1) over the first 20 s of recording. We used the dpHi caused 
by NH4Cl addition to calculate the cell buffer capacity. Nkcc2 cotransporter 
activity is therefore expressed as dpHi dt−1.
qRT-PCR. We used 50–200 mg of human renal tissue for total RNA extraction 
using the mirVana miRNA Isolation kit (Ambion, Life Technologies), follow-
ing the manufacturer’s protocol.
We extracted total RNA from mouse whole kidney by homogenization in TRIzol 
reagent (Invitrogen) and reverse-transcribed extracted RNA using the iScript kit 
(BioRad) according to the manufacturer’s instructions. We analyzed expression 
of target genes by qRT-PCR on LightCycler 480 (Roche) using the qPCR Core kit 
for SYBR Assay (Eurogentec SA). We designed specific primers using Primer 3 
(ref. 51) (primer sequences and PCR conditions available upon request). We 
determined amplification efficiency by dilution curves. We normalized UMOD 
expression in human samples to NKCC2 (SLC12A1), to account for TAL segment 
content in each renal tissue sample, and in mouse samples to Hprt1. We calculated 
the relative mRNA expression of genes of interest following the ∆∆CT method52.
Histology. We performed routine staining (PAS, Trichrome and H&E) accord-
ing to standard techniques. We stained heart sections with H&E for evalua-
tion by light microscopy, capturing digital images with a Mirax Midi digital 
camera (Zeiss).
We used PAS-stained renal sections (three sections per mouse or patient) 
for the quantification of histological features. The sections were independently 
examined and scored by two observers unaware of the mouse or patient geno-
type. Sections were viewed using a Zeiss Axioscope 40FL microscope (Carl Zeiss) 
equipped with an AxioCam MRc5 digital video camera. Images were recorded 
using AxioVision software 4.3 (Carl Zeiss). We assessed mesangial expansion 
and capillary loop dilation semiquantitatively (0, absent; 1, 1–50%; 2, 51–100% 
of the tuft area), as we did for interstitial inflammation and fibrosis, presence of 
tubular casts and tubular dilation (0, absent; 1, 1–30%; 2, 31–60%; 3, 61–100% 
of the whole section area). We quantified the presence of segmental and global 
glomerulosclerosis as percentage of the total number of glomeruli.
In mouse renal sections, we scored vascular damage as present or absent and 
quantitatively determined tunica media width in at least six vessels (average 
value of five or six measurements per vessel) per organ (n = 5 per group).
Immunofluorescence and immunohistochemistry. Kidney sections (4–5 µm 
thick) were first deparaffinized by heating for 60 min at 56 °C and subsequently 
hydrated in the following solutions (5 min each): 2× xylene, 100% ethanol, 80% 
ethanol, 70% ethanol and cold tap water. Antigenic retrieval was obtained by 
incubation with heated citrate buffer (0.01 M, pH 6.0), twice for 2.5 min.
For immunofluorescence (IF), slides were blocked in either 10% bovine serum 
albumin or 10% donkey serum (1 h at room temperature) and incubated for 1 h 
at room temperature with primary antibody and for 1 h at room temperature 
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with appropriate AlexaFluor-labeled secondary antibody (Life Technologies, 
1:500) All slides were viewed using a DM 5000B fluorescence upright micro-
scope (Leica DFC480 camera, Leica DFC Twain Software, 40× 0.75 lens; Leica 
Microsystems) or an LSM510Meta Confocal microscope (Zeiss) equipped with 
a 40× 1.4 Plan-Apochromat oil-immersion objective (Zeiss). We used identical 
acquisition parameters for the same antibody in different kidney sections.
Immunohistochemistry (IHC) was performed following standard protocols. 
Briefly, after antigen retrieval, sections were incubated for 15 min in 3% H2O2 to 
quench endogenous peroxidase activity. Sections were then blocked with 10% 
normal goat serum and incubated for 1 h at room temperature with primary anti-
body, followed by incubation for 30 min at room temperature with the biotinylated 
secondary antibody (Vector Laboratories, 1:300) and peroxidase-labeled strepta-
vidin (Invitrogen). Peroxidase activity was detected with 3,5-diaminobenzidine 
(Invitrogen). Sections were analyzed using a Zeiss Axioscope 40FL microscope 
equipped with an AxioCam MRc5 digital video camera (Carl Zeiss).
Immunoblotting. We homogenized mouse tissues from 6- to 24-week-old 
animals at 4 °C in lysis buffer (NaCl 150 mM, N-octylglucoside 60 mM, NaF 
10 mM, Na3VO4 1 mM, glycerophosphate 1 mM, Protease-Inhibitor Cocktail 
1:1,000 (Sigma-Aldrich) and Tris-HCl 20mM, pH 7.4). We obtained protein 
lysates from 16-month-old mice by solubilization of the tissue in lysis buffer, 
followed by sonication and centrifugation at 16,000g for 1 min at 4 °C, after 
which we used the supernatant. Alternatively, mouse tissues were homog-
enized in TRIzol (Invitrogen) and proteins were extracted after centrifugation 
at 11,000g for 15 min at 4 °C and collection of the organic phase that was then 
dialyzed against 0.1% SDS, precipitated with acetone and resuspended in PBS 
containing SDS 1%, NaF 10 mM, Na3VO4 1 mM, glycerophosphate 1 mM and 
Protease-Inhibitor Cocktail 1:1,000 (Sigma-Aldrich) (adapted from ref. 53). 
We analyzed the expression of Ncc and ENaC from kidney membrane prepara-
tions of 16-month-old mice as previously described54. Briefly, we homogenized 
kidneys in ice-cold lysis buffer (200 mM mannitol, 80 mM HEPES, 41 mM 
KOH, pH 7.5) with protease and phosphatase inhibitor cocktails (Complete 
ULTRA and PhosSTOP, Roche), obtained membrane preparations by ultracen-
trifugation (100,000g, 1 h, 4 °C) and solubilized in Laemmli buffer.
We obtained protein lysates from HEK cells 48 h after transfection by solu-
bilizing the cells in lysis buffer (NaCl 0.4 M; EGTA 0.5 mM; MgCl2 1.5 mM, 
Hepes 10 mM, pH 7.9; glycerol 5% (v/v); Nonidet P-40 0.5% (v/v) and protease 
inhibitors (Complete, Roche Diagnostics)). We assessed total and phosphor-
ylated Nkcc2 levels following immunoprecipitation with anti-Myc antibody 
(Clontech, 631206, 1:200). followed by affinity purification using protein 
G–agarose beads (Dynal). The purified immunocomplex was washed three 
times in PBS (Invitrogen).
Urinary proteins were precipitated with acetone, resuspended in PBS and sub-
sequently loaded onto gels with normalization to urinary creatinine levels.
Protein lysates, immunoprecipitated proteins or urinary proteins were sepa-
rated on 8–12% SDS-PAGE gel in nonreducing (total uromodulin) or in reducing 
(all other experiments) conditions and transferred onto nitrocellulose mem-
brane (GE Healthcare). We performed western blotting (WB) following standard 
protocols. Quantification was performed using the gel analysis option of ImageJ 
software (http://rsbweb.nih.gov/ij/).
Antibodies. We used the following antibodies: sheep polyclonal (Abcam, 
ab9029-1, 1:200 for IF and for IHC) and goat polyclonal (MP Biomedicals, 
55140, 1:1,000 for WB) antibodies against uromodulin, rat monoclonal anti-
body against HA (Roche, 11 867 423 001, 1:500 for IF and 1:1,000 for WB), rab-
bit polyclonal antibody against NKCC2 (Merck Millipore, AB3562P, 1:250 for 
IF and 1:1,000 for WB), rabbit polyclonal antibody against phospho-NKCC2 
(phosphorylated Thr96 and Thr101)55 (R5, 1:100 for IF and 1:750 for WB) (gift 
from B. Forbush), sheep antibody against SPAK (S150C, 1:1,000 for WB) and 
sheep polyclonal antibody against both phospho-SPAK (Thr243) and phos-
pho-OSR1 (Thr185)56 (S204C, 1:200 for IF and 1:2,000 for WB) (provided by 
D. Alessi), mouse monoclonal against OSR1 (OXSR1) (Abnova, H00009943-
M09, 1:500 for WB), rabbit polyclonal against total NCC54 (1:5,000 for WB), 
rabbit polyclonal against pT53NCC54 (1:5,000 for WB), rabbit polyclonal 
against pT58NCC54 (1:5,000 for WB), rabbit polyclonal against α-ENaC54 
(1:2,000 for WB), or rabbit polyclonal against γ-ENaC57 (1:20,000 for WB), 
goat polyclonal antibody against renin (Santa Cruz Biotechnology, sc-27318, 
1:500 for WB), rabbit polyclonal against ROMK (Chemicon, AB5196, 1:50 
for IF), goat polyclonal against ROMK (Santa Cruz Biotechnology, sc-10692, 
1:500 for WB), rabbit polyclonal antibody against aquaporin 2 (Sigma, A7310, 
1:200 for IF), goat polyclonal against Lipocalin 2/NGAL (R & D Systems, 
AF1857, 1:500 for WB), rabbit polyclonal against KIM-1 (TIM-1) (Novus 
Biologicals, NBP1-76701, 1:500 for WB), rabbit polyclonal antibody against 
calnexin (Sigma, C4731, 1:20,000 for WB) and mouse monoclonal antibody 
against β-actin (Sigma, A2228, 1:20,000 for WB).
In silico analysis. We analyzed the UMOD promoter sequence using 
Transcription Element Search Software (TESS) (http://www.cbil.upenn.edu/
cgi-bin/tess/tess) or PATCH 1.0 (http://www.gene-regulation.com/pub/pro-
grams.html) and the associated Transfac database (Computational Biology 
and Informatics Laboratory, University of Pennsylvania). We aligned promoter 
sequences with Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) and 
displayed them with Jalview (http://www.jalview.org/)58.
Statistical analyses. We performed comparisons between groups using a two-
tailed unpaired Student’s t-test, two-tailed nonparametric Mann-Whitney 
test or one-way ANOVA followed by Bonferroni’s post hoc test (when three 
groups were compared). Only statistically significant pairwise comparisons 
are indicated in the figures. We used a mixed linear model to explore the 
association of UMOD rs4293393 with square-root–transformed daytime uri-
nary uromodulin-to-creatinine ratio in order to better approximate a normal 
distribution of the residuals and to take familial correlations into account. 
We expressed continuous measures as mean ± s.d. and averages of measure-
ments as mean ± s.e.m. We set the significance level to P < 0.05.
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